Lila Kanani - Department of Toxicology, Faculty of Pharmacy, Islamic Azad University, Shahreza Branch, Shahreza, Iran
Azim Akbardeh Khiyavi - Department of Pilot Nanobiotechnology, Pasteur Institute of Iran, Tehran, Iran
Iraj Javadi - Department of Toxicology, Faculty of Pharmacy, Islamic Azad University, Shahreza Branch, Shahreza, Iran

Breast cancer is one of the most frequent cancer types within women population. Silibinin possesses abroad spectrum of biological applications such as anticancer activities[1]; however, poorbioavailabilityreducesits efficacy at the tumour sites.This study aimd to prepare nanoniosoaml silibinin and evaluate itscytotoxicity against T-47D breast cancer cell line. Niosomes were prepared by revers phase evaporationmethod. For this purpose, certain amount of span 80, silibinin, poly sorbet-80,PEG-3350 and cholesterolwere mixed together in chloroform. The solvent phase was evaporated by rotary evaporator and theremaining gellosephasewas hydrated in phosphate buffer saline. Mean size, size distribution and zetapotential of niosomes was measured by Zetasizer instrument[2]. Releasing pattern of drug was evaluatedby dialysis method and the cytotoxicity of nanoniosomes against T-47D cell line, was inspected by MTTassay[3]. Release study showed nanoparticles have proper silibinin retention capability. So our findingssuggest that silibinin niosomal nanocarriers could serve as a new drug formulation for breast cancertherapy.

Breast cancer, Silibinin, MTT assay